Elevated lipoprotein(a) [Lp(a)] levels were linked to a higher risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events, like myocardial infarction and stroke, but this threat may be attenuated by intensive low-density lipoprotein cholesterol (LDL-C)-lowering therapy.1
In the largest study to date of people living with CVD and a confirmed Lp(a) measurement, investigators analyzed data from more than 273,000 US individuals with ASCVD in the Family Heart Database, starting 30 days after diagnosis. The cohort’s size allowed investigators to assess the full Lp(a) spectrum, especially levels above 175–200 nmol/L.
“Among the many important findings in this study, we now know that in people living with CVD every nmol/L of Lp(a) confers increased risk of a subsequent cardiovascular event,” said Diane…